NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS), the gene-editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in two oral presentations and one poster presentation at the European Hematology Association (EHA) Annual Meeting. The meeting will be held from June 11th to 14th, 2015, in Vienna, Austria.
Help employers find you! Check out all the jobs and post your resume.
Cellectis (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS), the gene-editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in two oral presentations and one poster presentation at the European Hematology Association (EHA) Annual Meeting. The meeting will be held from June 11th to 14th, 2015, in Vienna, Austria.
Help employers find you! Check out all the jobs and post your resume.
